ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

Emil Kakkis

ultragenyx.com/ →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Why PROG Holdings (PRG) is a Great Dividend Stock Right Now

Why Toronto-Dominion Bank (TD) is a Great Dividend Stock Right Now

Goldman Sachs (GS) is a Top Dividend Stock Right Now: Should You Buy?

Why Union Pacific (UNP) is a Great Dividend Stock Right Now

Wells Fargo (WFC) Could Be a Great Choice

Micron stock slips 5% after earnings: should you buy the dip?

Red Cat Holdings: No Formal Guidance, Big Selloff - I Loaded The Truck

Tesla targets December 2026 for next-generation AI6 chip tape-out

AGRO or CTVA: Which Is the Better Value Stock Right Now?

ALSN vs. RACE: Which Stock Is the Better Value Option?

BTSG or ALHC: Which Is the Better Value Stock Right Now?

AXS vs. WRB: Which Stock Is the Better Value Option?

ALGN or WST: Which Is the Better Value Stock Right Now?

DECK vs. IDEXY: Which Stock Is the Better Value Option?

USFD vs. CELH: Which Stock Is the Better Value Option?

DRH or EGP: Which Is the Better Value Stock Right Now?

MGNI vs. BL: Which Stock Is the Better Value Option?

ACV Expands MAX Suite, Delivers AI-Powered, Profit-Focused Inventory Guidance with New ACV MAX Recommendations Feature

Why Is Louisiana-Pacific (LPX) Down 12.9% Since Last Earnings Report?

About